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Abstract
The Argonaute 2 (Ago2) protein is an essential effector protein in miRNA-mediated
mechanisms that regulate gene expression. Ago2 directly binds to the miRNA, form-
ing the RISC. RISC function is critical to controlling key biological processes and when
dysregulated can result in disease pathogenesis. Understanding Ago2 protein stability
and turnover will further our understanding in how RISC function is regulated. In hu-
man cells, we discovered a previously unidentified ~55 kDa protein that is a truncated
form of Ago2, that is formed from proteolytic cleavage of the full length Ago2 protein.
Further experiments are needed to determine (i) the detailed mechanism that forms
halfAgo2 (ii) the cellular or environmental triggers or stresses that initiate halfAgo2
production and (iii) if halfAgo2 has a potentially new role in gene regulation.
Introduction
miRNAs are endogenous small molecules that are essential regulators of human de-
velopment. miRNAs function by targeting the post-transcriptional stages of gene ex-
pression, via several distinct mechanisms [1]. miRNA regulatory function depends on
the miRNA directly binding to an Argonaute (Ago) protein, forming the RNA Induced
Silencing Complex (RISC). In this complex the miRNA acts a guide, by binding to a
complementary site within mRNA and bringing the RISC, and its associated regulatory
proteins, to the target [2] [3].
RISC regulates key biological processes, therefore any disruption to RISC function can
have severe consequences, and misregulation of RISC is implicated in the development
of disease [4]. It is therefore important that the stability of RISC and accordingly its
components, miRNA andAgo, are controlled. There are several knownmechanisms that
mediatemiRNA stability and turnover, including homeostatic and feedbackmechanisms
that coordinate miRNA levels with Ago levels [5] [6] [7] [8]. However, we have only
limited understanding into mechanisms that regulate the turnover of Ago proteins and
the RISC complex.
There is emerging evidence that Ago function and stability is mediated by a variety of
post-translational modifications of the protein, which occurs as a consequence of com-
plex signalling pathways [9] [10] [11] [12] [13]. These modifications can alter protein
function, stability, and localisation. Depending on the modification, these changes can
be permanent or reversible. Therefore Ago levels are potentially highly dynamic and
are responsive to internal and external stimuli.
While the 4 human Ago proteins (1–4) display some functional redundancy, Ago2 is the
most abundant in commonly used human cell lines [14] and the most studied in miRNA
regulation.
Objective
While analysing the protein expression of full-length (FL), endogenous, Ago2 (~85 kDa)
in HeLa cell lysate, we observed that an Ago2-specific monoclonal antibody targeted to
the N-terminus of the protein [15], also bound to a previously unidentified protein of
approximately 55 kDa. The objective of this study was to investigate this 55 kDa protein,
and to test our hypothesis that this protein is a truncated form of FL human Ago2.
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Figure Legend
Figure 1. Endogenous and recombinant Ago2 can form a stable, truncated pro-
tein: halfAgo2.
(A) Full length (FL) Ago2 (~85 kDa) and halfAgo2 (~55 kda; indicated by the arrow) are
expressed in a variety of immortalized human cell lines.
(B) HeLa cells treated with siRNA that specifically targets the Ago2 open reading
frame/coding sequence (Ago2 ORF) decreases expression of both FL Ago2 and halfAgo2.
Using an alternate Ago2-specific siRNA that binds to the 3‘UTR of the FL gene (Ago2
3‘UTR) both FL Ago2 and halfAgo2 protein expression is similarly decreased when com-
pared to control.
(C) halfAgo2 does not contain the PIWI domain. The expression of Ago proteins in
HeLa lysate was tested with an antibody that specifically binds to the C-terminal PIWI
domain. Only FL Ago proteins were visible.
(D)Transiently expressed N-terminally tagged FLAG::Ago2 also produced a stable, trun-
cated N-terminal Ago2 product. The expression of FLAG::halfAgo2 is inhibited when
treated with an siRNA that can target this plasmid by targeting the Ago2 ORF, but is
unaffected when treated with an siRNA that cannot target the plasmid (siRNA targeting
Ago2 3‘UTR).
(E) FL Ago2 and halfAgo2 protein levels accumulate when the proteasome is inhibited
by MG132 treatment in HeLa cells. Expression normalised to DMSO control (n=3).
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Results & Discussion
We initially observed the unidentified 55 kDa protein, predicted to be a truncated Ago2
protein which includes the N-terminus of the FL Ago2 protein, in HeLa cells. To ensure
that this phenomenon was not cell line specific, we tested several human immortalised
cell lines, derived from a variety of tissues (breast, bone and cervix) (Fig. 1A, S1). We
detected the 55 kDa band in the majority of all samples tested, with variable expres-
sion levels between cell lines. As other proteins tested in these lysates show no signs of
degradation, we can also conclude that the 55 kDa protein is not due to general degrada-
tion of the cell lysate (Fig. S1). These data suggests the production of the 55 kDa protein
is a regulated process, with a potential physiological function.
To eliminate the possibility that the 55 kDa band is a non-specific band cross-reacting
with the N-terminal targeting Ago2 antibody, we wished to see if the expression of
the 55 kDa band was dependent on FL Ago2 protein expression. We used an siRNA
that specifically targets the open reading frame (ORF) of the Ago2 transcript, which
will reduce FL Ago2 protein expression level. When FL Ago2 protein expression was
knocked down, we observed that the 55 kDa protein expression levels also decreased
when compared to the control samples (Fig. 1B). To confirm this result we repeated the
Ago2 knockdown with an independent siRNA that targeted a different segment of the
FL Ago2 transcript, the 3‘UTR. This experiment produced similar results, with reduced
protein expression of both the FL Ago2 and the 55 kDa protein, suggesting this effect is
not due to off-target effects of the siRNAs used. These data indicate that FL Ago2 RNA
production is required for the 55 kDa protein to be present. Furthermore, there are no
identified alternatively spliced Ago2 isoforms that include the 3‘UTR sequence of the
FL Ago2 transcript. This suggests the truncated protein is not a product of alternative
splicing.
Due to the size of this protein (~55 kDa) and that it contains the N-terminal domain
of Ago2, we predicted that this truncated Ago2 does not contain the PIWI domain (re-
quired for target cleavage and binding the 5‘ end of mature miRNAs) present in the FL
Ago2, as this domain is located near the C-terminus of the protein. To investigate this
we used an antibody that targets the PIWI domain of human Ago proteins (Fig. 1C).This
antibody only recognises FL Ago proteins, confirming that the 55 kDa truncated protein
does not contain the PIWI domain, and therefore potentially functions independently
of binding miRNAs. This data suggests that after FL Ago2 cleavage, the N-terminal con-
taining polypeptide (halfAgo2) is more stable than the C-terminal containing product,
suggesting halfAgo2 has an independent function. The N-terminal domain of Ago2 has
an essential role in separating the strands of miRNA duplexes [16], while the adjacent
PAZ domain can bind to the 3‘ end of RNA molecules [17]. These functional properties
indicate that halfAgo2 could play a role in independent gene regulatory mechanisms.
To further investigate the origin of the 55 kDa protein, we transiently expressed a FLAG-
tagged FL Ago2 gene expression plasmid into HeLa cells. The FLAG tag is situated at the
N-terminus of the protein, and therefore the tag will be present in a truncated product
derived from the exogenous FL Ago2 that includes the N-terminal domain. This plas-
mid contains the endogenous FL Ago2 ORF, but contains plasmid specific sequences
upstream and downstream of the Ago2 coding sequence. When examining the lysate
for FLAG-tagged proteins we also observed a FLAG-tagged truncated 55 kDa protein
(Fig. 1D). When samples expressing the FLAG-Ago2 plasmid were also transfected with
an siRNA that targets the Ago2 ORF, and could therefore target the FLAG-Ago2 tran-
script, expression of both the FLAG-tagged FL Ago2 and the smaller 55kDa protein was
reduced. However, neither of their expression was altered when treated with the Ago2
3‘UTR targeting siRNA, which exclusively targets endogenous Ago2 expression as it is
incapable of binding to the FLAG-Ago2 transcript (Fig. 1D).
As the expression of the exogenous, FLAG-tagged Ago2 is derived from a cDNA se-
quence of the FL Ago2 transcript that has been inserted into an expression vector, the
sequence does not contain introns. Therefore, FLAG-Ago2 expression is independent of
splicing mechanisms. As FLAG-halfAgo2 expression is observed, this further suggests
that this protein is not the result of alternative splicing, but may instead be formed from
proteolytic cleavage of the FL Ago2 protein. We can conclude from this data that the 55
kDa Ago2 band is most likely derived from a post-translational mechanism that targets
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the FL Ago2 protein. We will refer to this Ago2 protein as halfAgo2.
We investigated if, like FL Ago2, degradation of the 55 kDa Ago2 protein is mediated by
the 26S proteasome [18]. We treated HeLa cells with the proteasome inhibitor MG132
and found that both FL Ago2 and the 55 kDa Ago2 protein levels accumulated upon
proteasome inhibition, indicating that the turnover of both these proteins is protea-
some dependent (Fig. 1E). However halfAgo2 accumulation was greater than FL Ago2,
signifying that halfAgo2 is a less stable protein that FL Ago2. We confirmed that accu-
mulation of Ago2 protein was via a post-transcriptional mechanism as Ago2 transcript
levels remain unchanged in MG132 treated samples (Fig. S1).
There is precedent in the literature that alternate forms of key proteins of the small RNA
pathway have distinct roles to the full length form. Dicer, which is responsible for key
steps of small RNA biogenesis, is proteolytically cleaved to form a highly-expressed, sta-
ble fragment (sDCR-1) that functions independently of full length Dicer, but has distinct
regulatory functions in both the RNAi and miRNA pathways [19]. Our data suggests
that halfAgo2 is a stable truncated form of Ago2, and further studies are required to un-
derstand the function of halfAgo2 and the implications this has on Ago2 protein stability
and RISC function.
Based on the size of the halfAgo2 protein, we predict halfAgo2 contains a functional PAZ
domain, and therefore can potentially still bind small RNA molecules. This creates the
possibility that halfAgo2 and FL Ago2 may be in competition for co-factor association
and/or small RNA binding. Alternatively, halfAgo2 may bind to a unique set of RNA
molecules forming a distinct regulatory complex. This possibility would expand the
range of traditional Ago2 targets currently being investigated and may help to explain
the number of predicted Ago2 targets, as identified by high-throughput immunoprecip-
itation and RNA-protein crosslinking experiments, which have no associated miRNA
binding sites [20].
As factors that influence Ago2 and RISC stability are largely unknown, discovery of the
novel mechanism behind halfAgo2 production and what regulates this mechanism, is
essential to fully understand the role of Ago2 stability in regulation of gene expression in
both healthy tissues. Additionally, this will provide critical insights into how the Ago2
and RISC complex responds to stress, and how they become dysregulated in disease
pathogenesis.
As there is increasing evidence that Ago2 function, stability and turnover is regulated by
post-translation modifications of the protein which are the result of a complex network
of signalling pathways, it would be interesting to investigate if halfAgo2 production is
a consequence of such a modification. If so, it suggests halfAgo2 formation is regulated
in response to specific cellular or environmental triggers or stresses, as a mechanism to
control RISC function in these particular situations.
halfAgo2 is a stable protein product which potentially has its own unique regulatory
role. halfAgo2 may play a role in RISC formation or activity, or alternatively, is capable
of functioning independently from the miRNA pathway. Elucidating the production
and function of halfAgo2 will further our understanding of Ago2 stability and therefore
miRNA expression and function. This can impact the development of future therapeutics
which act to overexpress or inhibit miRNA function.
Conclusions
Our results indicate that unloaded human Ago2 can form a stable protein product, of
approximately 55 kDa, called halfAgo2. We propose that halfAgo2 is produced from the
post-transcriptional proteolytic cleavage of Ago2. We predict that halfAgo2 is formed
as a consequence of a mechanism which controls Ago2 stability and turnover.
Limitations
Due to the nature of this study and the current tools available we are unable to isolate en-
dogenous halfAgo2. This is because Ago family members are highly conserved. There-
fore, the development of Ago2 specific antibodies depends on a unique N-terminal do-
main only present in Ago2. However, the N-terminal domain is also present in halfAgo2.
It is therefore impossible to separate full length Ago2 from halfAgo2 via immunopre-
cipitation, or other antibody based methods. It will therefore be necessary to accurately
map what is encoded within the halfAgo2 protein, to better understand its potential
functions and so halfAgo2 constructs can be generated. Alternatively, halfAgo2 can be
purified via size exclusion chromatography.
We propose that halfAgo2 is formed as a consequence of a proteolytic cleavage mecha-
nism which controls Ago2 stability and turnover. There is mounting evidence that Ago2
stability is regulated by post-translational modifications (PTMs) of the protein. Asmany
sites of PTMs have been predicted within the FL Ago2 protein, only a few have known
functional consequences [9]. Therefore it would be interesting to investigate if the for-
mation of halfAgo2 was precipitated by such a modification. And if so, identify the
signalling pathways involved in triggering this mechanism, and the specific stresses or
environmental triggers required to prompt such a signalling cascade, as there is evi-
dence that PTMs can control RISC activity and miRNA regulation efficiency in a signal
dependent manner [11].
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